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Cystic fibrosis (CF) is a multisystem disorder with significantly shortened life expectancy. 
The major cause of mortality and morbidity is lung disease with increasing pulmonary 
exacerbations and decline in lung function predicting significantly poorer outcomes. The 
pathogenesis of lung disease in CF is characterised in part by decreased airway surface liquid 
volume and subsequent failure of normal mucociliary clearance. This leads to accumulation 
of viscous mucus in the CF airway, providing an ideal environment for bacterial pathogens to 
grow and colonise, propagating airway inflammation in CF. The use of nebulised hypertonic 
saline (HTS) treatments has been shown to improve mucus clearance in CF and impact 
positively upon exacerbations, quality of life, and lung function. Several mechanisms of HTS 
likely improve outcome, resulting in clinically relevant enhancement in disease parameters 
related to increase in mucociliary clearance. There is increasing evidence to suggest that HTS 
is also beneficial through its anti-inflammatory properties and its ability to reduce bacterial 
activity and biofilm formation. This review will first describe the use of HTS in treatment of 
CF focusing on its efficacy and tolerability. The emphasis will then change to the potential 
benefits of aerosolized HTS for the attenuation of receptor mediated neutrophil functions, 
including down-regulation of oxidative burst activity, adhesion molecule expression, and the 









An introduction to cystic fibrosis and the role of neutrophils in developing airways 
disease 
Cystic fibrosis (CF) is a complex genetic disease leading to increased risk of chronic lung 
disease resulting in terminal respiratory failure [1, 2]. CF is an autosomal recessive disorder 
caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride 
channel. Over 1900 CFTR mutations leading to defective chloride transport have been 
identified to date [3] and result in misfolding of the CFTR protein. Reported mutations can be 
categorised into different classes depending on whether the mutation alters CFTR processing 
(Classes I, II and V) or results in dysregulated chloride secretion (Classes III, IV, VI) (Figure 
1). The most common mutation is deletion of phenylalanine at position 508 (∆F508) which 
occurs in approximately 70% of patients with CF, and 90% of CF suffers carry one copy [4]. 
Defects in CFTR protein function not only impact upon cAMP-dependent chloride secretion 
but also result in increased epithelial sodium channel (ENaC)-mediated ion absorption in the 
superficial airway epithelium [5, 6]. CFTR absence or malfunction causes increased water re-
absorption across airway epithelial cells leading to dehydration of the airway surface liquid 
(ASL) layer, persistent mucus hypersecretion and airflow obstruction [7]. Dehydration of the 
airway surface liquid layer and mucus accumulation has been implicated in exacerbated 
airway inflammation [8] and decline in lung function predicts significantly poorer outcomes 
[9]
. Therapeutic interventions to improve mucus clearance is a necessary treatment in CF [10]. 
HTS at concentrations of 3% or higher is widely used to improve mucociliary clearance, as 
this increases the tonicity of the ASL creating an osmotic gradient drawing water into the 
airway hence improving ASL and facilitating removal of airway secretions (Figure 2). 
Furthermore, HTS improves lung function and quality of life and significantly decreases the 
frequency of exacerbations [11, 12] and is generally well tolerated.  
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When considering the different immune cells present in the CF lung it has been 
documented that neutrophils account for approximately 60-70% of immune cells in CF 
airway samples [13]. Key studies have demonstrated that infiltration of neutrophils into the 
airways occurs early in the course of CF lung disease and that neutrophil-released granule 
proteins, particularly neutrophil elastase (NE), play a crucial pathological role [14, 15]. The 
expression of functional CFTR on the plasma membrane of neutrophils has been the topic of 
great debate [16-19] with studies specifying intrinsic abnormalities due to a lack of CFTR 
function [20, 21]. Reports on reprogrammed cell activity secondary to chronic bacterial 
infection and inflammation have also been documented [22]. Moreover, persistent mTOR and 
CREB pathway activation in CF airway neutrophils [23] and augmented cell surface nutrient 
transporter expression are consistent with metabolic adaptation [24].  
Regardless of the cause of impaired neutrophil activity however, the fundamental 
consequence is neutrophil mediated tissue proteolysis. Excessive neutrophil recruitment to 
the lung, results in prolific NE degrading protease activity and inflammation that can 
eventually become chronic and lead to tissue destruction. The recognition that aerosolized 
HTS may moderate neutrophil cytotoxicity and may function to restrain an exuberant 
inflammatory response in CF, provides a possible strategy for mitigating inappropriate 
neutrophil activity. This review will initially describe the use of HTS in treatment of CF and 
then extend the focus of HTS beyond mucociliary, to the potential benefits of aerosolized 
hyperosmolar therapy for the modulation of neutrophil activity within the confines of the CF 
airways. Our review of the literature was carried out using the MEDLINE database (from 
1976 to the year 2014), Google Scholar and The Cochrane Library databases using several 




The clinical efficacy of nebulised HTS in CF 
The use of HTS treatments has been shown to improve mucus clearance in CF and impact 
upon exacerbations, quality of life and improve lung function [12]. Early studies demonstrated 
an acute dose–response relationship between inhaled saline concentration and mucociliary 
clearance [25], with short-term HTS administration improving mucociliary clearance and lung 
function with acceptable tolerability [26]. In 2006, the National Hypertonic Saline in Cystic 
Fibrosis Study Group provided the first evidence for the long-term efficacy of HTS in 
individuals with CF. The study randomised 164 patients with CF to receive HTS (7%) or 
isotonic (0.9%) saline for 48 weeks. Using forced vital capacity (FVC) and forced expiratory 
volume in 1 second (FEV1) to assess the rate of change of lung function, no significant 
difference was observed between the two groups, but there was a statistically significant 
difference in the absolute change in lung function. More importantly, this study demonstrated 
an impressive reduction in the frequency of exacerbations in the HTS group, with fewer days 
missed from work or school. Furthermore, significant improvements in quality of life were 
observed, particularly with regard to mental health on quality of life questionnaires after 
long-term HTS therapy [12].  
A further study by Donaldson et al. showed that repeated use of 7% HTS generated 
both acute and sustained improvements in mucociliary clearance while improving FEV1 
following four-times-daily treatment for 14 days, when compared to HTS given in 
conjunction with the ENaC inhibitor amiloride [26], however this study lacked a 0.9% saline 
control group, and as a result the effect of HTS could only be compared to patient baselines. 
Robinson et al, in a study employing radioaerosol technique, examined the acute effect of a 
single administration by aerosolization of 7% HTS, amiloride, or a combination of HTS and 
amiloride, or a 0.9% saline control [27]. Results demonstrated that treatment with HTS alone 
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significantly increased mucociliary clearance compared to treatment with HTS/amiloride 
combined, and both of these therapies were in turn significantly more effective than isotonic 
saline or amiloride alone.  
The efficacy of HTS in improving mucociliary clearance may also be related to the 
volume administered as studies of 4ml or 5ml aerosolized HTS  [12, 26] recorded smaller 
improvements in lung function compared to a 10ml volume [11, 28]. In 2011, Dmello et al. used 
a multivariate logistic regression analysis to assess 340 CF exacerbations, 99 of them 
involving treatment with HTS. The results confirmed the beneficial effect of HTS with regard 
to reduction of pulmonary exacerbation frequency, even in those with “severe” CF lung 
disease, categorised as those with an FEV1 below 40% [29]. A further study, on the use of 
HTS during hospitalization for adult exacerbations of CF showed that nebulized treatment 
accelerated the recovery of FEV1 to baseline [30]. However, there is conflicting evidence on 
the effectiveness of HTS upon lung function and FEV1 and a Cochrane review summarising 
all clinical trials of HTS in CF demonstrated a significant but minimal increase in FEV1 with 
a mean change of 4.15% after 4 weeks, however at 48 weeks this was not significant and was 
reduced to 2.31% [31].  
While spirometry, primarily FEV1, represents the measure of lung function used in 
the majority of HTS studies to date, the use of lung clearance index (LCI), a measure of 
ventilation inhomogeneity derived from the multiple breath washout (MBW) test, is 
increasingly being employed for the early detection of CF respiratory disease [32]. LCI has 
been shown to be a better predictor of later lung function abnormalities than FEV1 [33] and 
also correlates well with structural changes [34, 35]. LCI has been shown to detect treatment 
responses to HTS in children with CF aged 6-18 years who have normal baseline spirometry 
[36]
. It should be noted that while these studies when analysed together formed the basis for 
7 
 
HTS use in the majority of CF centres in Europe and North America, the data for the most 
part only apply to adults, with a relative lack of evidence for use in children. Studies of HTS 
use in the CF child population have shown satisfactory safety and tolerability profiles [37-39], 
but it is still unclear as to whether or not HTS treatment confers a clinical benefit upon this 
group. This may be in part due to the fact that younger individuals typically have less-
advanced lung disease, nonetheless it is still well tolerated even in very young children aged 
between 12 and 30 months [38]. Although there is good evidence to suggest that HTS is of 
benefit regarding the enhancement of mucociliary clearance in adults, one study of HTS in 
CF children aged between 7-14 years published by Laube et al. demonstrated only negligible 
acute clearance effects [40], however, it should be noted, that this was a single-dose study. A 
recent trial, from the North Carolina group at Chapel Hill, of HTS in CF children with normal 
lung function has shown some interesting results. This trial compares 6% HTS to 0.12% 
saline, with both arms of the study receiving 4ml three times daily for four weeks. While 
mucociliary clearance was largely unaltered at 2 hours after the initial dose, a significant 
acceleration of mucociliary clearance lasting greater than 12 hours following the final dose 
was observed [41]. This sustained effect suggests that single-dose studies may not be ideal 
predictors of mucociliary clearance in these individuals.  A further study, by Amin et al. 
using LCI to evaluate ventilation heterogeneity in individuals aged between 6 and 18 years 
with CF with normal spirometry, demonstrated a significant improvement in ventilation after 
four weeks of HTS treatment [36]. Moreover, recent evidence has demonstrated that HTS is 
also beneficial through its ability to reduce Pseudomonas aeruginosa activity [42] and also to 





Tolerability of HTS in cystic fibrosis 
Although an acute dose–response relationship between inhaled saline concentration and 
mucociliary clearance exists, data showing better or worse clinical efficacy with 
concentrations other than 7% are lacking. In this regard most clinical trials show that both 3% 
and 7% HTS are more effective than placebo [31], however one clinical trial in a paediatric 
population demonstrated a superior effect with 3% HTS. In this study, the 3% group had 
significantly higher FEV1 on day 14 and day 28 compared to the group receiving 7% [44], 
however this study was not extended beyond 28 days, so it is unclear whether there is a truly 
superior dose, and the majority of trials have employed 7% HTS. Moreover, the percentage 
of HTS administered not only has implications for clinical efficacy, but also for patient 
adherence, since as doses increase (from 3% to 7%), so do nebulisation times, taste and 
tolerability, all important factors for compliance [45]. A 1997 study by Robinson et al. 
showing increasing levels of sputum clearance with increasing concentrations of saline also 
noted that factors such as cough and oropharyngeal irritation increased in tandem with 
sputum clearance, and were highly disconcerting at concentrations approaching 12%, setting 
the ceiling of tolerability for the study [25]. Tolerability is often a key determinant of the dose 
selected for an individual patient, with pre-treatment with bronchodilators aimed at 
facilitating a higher concentration. Roughly 5% of CF patients undergoing treatment with 
HTS will experience bronchospasm severe enough to restrict use [8]. A commonly-used 
starting point for HTS is 7%, with bronchodilator pre-treatment, and with the willingness to 
down-titrate should patient comfort be sufficiently compromised. Administration of 7% HTS 
in conjunction with 0.1% hyaluronic acid via the aerosolised route has been shown to 




The effect of HTS on levels of airway inflammatory mediators involved in neutrophil 
recruitment and activation 
Circulating neutrophils are initially found in a resting state, and become primed upon 
exposure to chemotactic stimuli comprising pathogenic molecules such as N-formyl peptides, 
cytokines including tumour necrosis factor-α (TNF-α) and chemokines including 
interleukin(IL)-8 [47]. The release of cytokines and chemokines including IL-8 and 
granulocyte macrophage colony stimulating factor (GM-CSF) by CF epithelial cells functions 
to signal to circulating immune cells resulting in increased numbers of neutrophils and 
macrophages localized to the airways [48, 49]. IL-8 binds to the chemokine (C-X-C motif) 
receptor 1 (CXCR1) and CXCR2 on the plasma membrane of neutrophils resulting in cell 
adhesion [50] and migration [51]. In turn, synthesis and release of TNF-α and IL-1β by 
recruited macrophages, and NE induced secretion of IL-8 and IL-6 by upper airway epithelial 
cells, perpetuate the cycle of inflammation [52, 53]. In addition, NE activity in BAL fluid is 
associated with early airways disease in children with CF [54] and both NE and TNF-α up-
regulate leukotriene B4 (LTB4) production by macrophages [55, 56], the latter a potent lipid 
inflammatory mediator. It has also been documented that CF lung epithelial cells release IL-8 
in the absence of pathogens suggesting a persistent pro-inflammatory state.  Moreover, upon 
bacterial challenge studies have shown that the level of IL-8 released in response to infection 
is significantly increased in CF airway epithelial cells compared to CFTR sufficient cells and 
this has in part been explained by the plasma membrane surface expression of 
asialoganglioside 1 and toll-like receptor 4 [57, 58].  
Observations of increased cell migration and neutrophil-dominated chronic airway 
inflammation at an early age in children with CF [59], supports the need for potential therapies 
that may target airway inflammatory mediators of neutrophil priming and migration. In this 
regard the ability of HTS to act as an anti-inflammatory, or alternatively pro-inflammatory 
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agent, was studied by Chan and colleagues (2006) [60]. IB3-1 bronchial epithelial cells 
containing the DF508/W1282X CF mutation were exposed to increasing concentrations of 
HTS ex vivo and secreted IL-8 levels were quantified. Results revealed that CFTR mutated 
bronchial epithelial cells produced an exaggerated level of both basal and NaCl-induced IL-8 
production, indicating that HTS was acting as a pro-inflammatory stimuli [60].  However, the 
highest concentration of HTS employed in this study was 125mM, which is in contrast to the 
therapeutic concentration of HTS used in vivo (513mM; 3%). Nevertheless, this effect of 
HTS was echoed by studies that demonstrated that hyperosmolar solutions stimulated 
cytokine production by bronchial epithelial cells via p38 mitogen-activated protein kinases 
activation [61] and in CF bronchial gland cells via the NF-κB pathway [62]. Similarly, a study 
carried out by Shapiro et al. (1997) demonstrated that human peripheral blood mononuclear 
cells exposed to increasing concentrations of NaCl in combination with bacterial 




In contrast to the HTS-induced increased expression of IL-8 in in vitro studies, a 
number of in vivo studies have measured IL-8 levels following HTS treatment. These 
included a long term controlled trial of inhaled HTS in patients with CF, compared to inhaled 
isotonic saline, with no significant difference in sputum IL-8 levels found between the groups 
[64]
. Two further studies also investigated IL-8 levels in CF sputum post HTS (3% and 7%) 
nebulisation, with results showing no significant alteration in IL-8 levels [65, 66]. Moreover, an 
investigation designed to assess the effect of 7% HTS on airway inflammation in CF, with 
outcome measurements including altered IL-8, myeloperoxidase (MPO) and NE levels, 
revealed no increase in free IL-8 and the study did not support the capacity of HTS to 
promote inflammation in CF [67]. Furthermore, in human pulmonary microvascular 
endothelial cells the ability of increasing concentrations of HTS (ranging from 140mM to 
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170mM NaCl) to significantly reduce TNF-α-induced IL-8 release was established [68]  
however, the concentration of HTS utilised was far below that used therapeutically. More 
recently, the functionality of HTS in reducing levels of IL-8 bound to glycosaminoglycans 
(GAGs) within the CF airways was observed. Within the CF airways, the dehydrated thick 
mucus contains raised levels of anionic GAGs formed on the surface of bronchial epithelial 
cell [69], the most abundant including heparan sulphate (HS) and chondroitin sulphate (CS) [70, 
71]
. Of major importance, increased quantities of GAGs have been found in airway samples 
from individuals with CF [72]. The immobilization of IL-8 by GAGs plays a major role in the 
establishment of gradients of the chemokine that contribute to the recruitment of neutrophils 
during inflammatory exacerbations [73]. The use of an IL-8 decoy (PA401) with enhanced 
GAG binding ability [74], or the removal of HS and CS lead to a significant reduction in the 
detection of this chemokine [75]. Moreover, disruption of this interaction with increasing ionic 
concentrations (7% HTS) displaces IL-8 from GAGs, subjecting the former to clearance by 
proteolytic activity by NE [76] (Figure 3). Although only a small number of patients were 
recruited to this latter study, and the effect of HTS on other immunomodulatory mediators in 
the CF airways was not evaluated, results are in line with the ability of aerosolized HTS in an 
animal model of acute lung injury to reduce levels of the murine analogue of IL-8, cytokine-
induced neutrophil chemoattractant-1, by 44% [77].    
 
The ability of HTS to impact upon neutrophil adhesion and migration. 
Pro-inflammatory stimuli, either individually or in combination, can stimulate the neutrophil 
to change morphology and migrate to the airways, the latter being a multistep process. 
Initially, after a chemotatic signal is received, the neutrophil reversibly binds to the vascular 
endothelium through the interactions between P-selectin and E-selectin found on the 
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epithelium, with L-selectin expressed on the neutrophil surface. Rolling of neutrophils 
involves interaction between these selectins and glycoproteins such as P-selectin glycoprotein 
ligand (PSGL1) which is expressed by the endothelium and leukocytes. This mediated rolling 
of the cell allows new bonds to form before breaking of older bonds and shedding of L-
selectin [78]. This slow rolling then allows for tighter bonds to form between β2 integrins 
expressed on the neutrophil surface including CD11b/CD18 and the corresponding ligands, 
intercellular adhesion molecule-1 (ICAM-1) and ICAM-2. Once neutrophils have adhered to 
the endothelial wall, tight junctions between endothelial cells become loose and allow 
transmigration. Neutrophils then follow a gradient of immobilised chemoattractants and 
travel to the airways along collagen and elastin fibres [78] and movement through the 
extracellular matrix is facilitated by release of proteolytic enzymes including 
metalloproteases and NE [79, 80].  
The capacity of HTS to reduce neutrophil migration as a result of lowering levels of 
the potent neutrophil chemoattractant IL-8 has been investigated. In this regard, the 
consequence of disruption of interactions between IL-8 and GAGs within the CF lung was 
addressed by assessing the chemotactic potency of sputum ex vivo following nebulized HTS 
treatment, with results demonstrating a reduction in the neutrophil chemotactic index [76]. 
Although IL-8 is a major chemotactic factor in CF, it is not the only chemoattractant found in 
the CF airways. Thus this latter study should be extended to evaluate the effect of HTS on 
additional chemoattractants including levels of formyl peptides, C5a [81], and the more 
recently described chemotactic peptide, proline-glycine-proline [82]. Nevertheless, in 
agreement with these latter findings, Aitken et al (2003) showed that the percentage of 
neutrophils in liquefied sputum samples significantly decreased post HTS (3%) nebulization 
[65]
. Moreover, recent data indicates that HTS can inhibit platelet activating factor (PAF) 
stimulated cell adhesion. In this regard, exposure of neutrophils to PAF characteristically 
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leads to increased CD11b/CD18 surface expression, and adhesion of PAF activated 
neutrophils was significantly inhibited by pretreatment with HTS, indicating that HTS may 
influence functional changes in neutrophils [68]. This concept is further supported by a study 
demonstrating that HTS considerably reduced neutrophil chemotaxis in response to zymosan-
activated serum [83]. Moreover, HTS treatment decreased the number of neutrophils migrating 
to the airways in a rat model [84], and has been shown to reduce neutrophil adhesion and 
rolling in a murine model [85]. Although this latter study did not evaluate the neutrophil 
plasma membrane surface expression of either L-selection or CD11b, diminished levels of 
both adhesion molecules in response to HTS had previously been documented [86, 87]. 
Moreover, while the use of animal models provides in-depth information on the efficacy of 
HTS usage, they are not representative of human disease and in particular the use of murine 
models in the study of CF is limited, as CF mice fail to develop spontaneous lung disease or 
chronic bacterial infection [88].   
 
The impact of HTS on neutrophil cellular processes including NADPH oxidase activity 
and degranulation 
The process of neutrophil mediated bacterial clearance can be divided into two main 
procedures, those that are oxygen independent, and those that are oxygen dependent. These 
two cell processes are tightly regulated, and upon dysregulation, can result in release of 
reactive oxygen species and proteolytic enzymes to the surrounding lung tissues, as occurs in 
CF. Reactive oxygen species are produced by reduction of consumed oxygen. This reaction is 
catalysed by the NADPH oxidase, an enzyme complex that consists of two membrane 
proteins, p22phox and gp91phox, that constitute the heterodimeric flavoprotein cytochrome b558, 
and four cytosolic components p67phox, p47phox, p40phox and p21rac (Figure 4). In the resting 
neutrophil the majority of membrane-associated flavoprotein cytochrome b558 is localised to 
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secondary granules and the plasma membrane, whereas components p67phox, p47phox and 
p40phox are localised within the cytosol together with GDP-bound p21rac. Upon priming of the 
neutrophil with proinflammatory stimuli including fMLP or TNF-α, partial assembly of the 
NADPH oxidase occurs involving phosphorylation of p67phox and p47phox followed by 
translocation to the flavocytochrome. The NADPH oxidase complex becomes fully 
assembled upon recruitment of GTP-bound p21rac. Upon assembly, the active oxidase reduces 
NADPH and electrons are transferred via the flavocytochrome across the membrane to 
oxygen creating superoxide (O2-), which dismutates to hydrogen peroxide (H2O2). H2O2 
generated during the oxidative burst has limited bactericidal properties and the best-defined 
function of H2O2 in the antimicrobial activities of neutrophils comes from the function of 
H2O2 as a substrate for MPO in the presence of halides (chloride (Cl-)), resulting in the 
formation of hypochlorous acid (HOCl). HOCl is the most bactericidal oxidant known to be 
produced by neutrophils and as Dakin’s solution, was extensively used in medicine in the 
treatment of topical wounds until antibiotics became available. Conversely, neutrophil-
derived reactive oxygen species have been implicated in activation of NF-κB, release of pro-
inflammatory mediators, inhibition of apoptosis and recurring DNA damage [89]. 
 The second mechanism contributing to bacterial killing is mediated by enzymes 
stored in granules (Figure 5). Essential serine proteases stored in primary granules include 
NE, cathepsin G and proteinase 3. Each azurophilic granule contains 5.33mM NE, 
corresponding to ~67000 molecules per granule. NE, protease 3 and cathepsin G, are found in 
similar amounts and distribution in neutrophils [90], however much of the research has focused 
on NE as it is the main mediator of proteolysis (Figure 6). As NE up-regulates expression of 
other proteases it has been suggested that neutralization of NE activity is central to reducing 
the overall protease burden within the airways [91].  In addition, NE plays a central role in 
activation of MMPs which are synthesized in an inactive zymogen precursor form [92]. For 
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example, MMP-9 which exists as a pro-form, exhibits a molecular mass of 92 kDa which is 
cleaved by NE into an active molecule that is 72-kDa in size [93]. In turn, increased levels of 
active MMP-9 can lead to the increased production of chemotactic peptides [94] and extensive 
airway remodelling and inflammation [95, 96]. Thus, of the serine proteases, NE is the most 
harmful in the lung [97] and it has been proposed as a target for therapeutic intervention in CF 
[98, 99]
. Unopposed NE proteolytic action can degrade molecules important in control of 
inflammation including receptors [100], particularly those required for clearance of apoptotic 
neutrophils [101] or bacterial phagocytosis [102, 103]. NE can also inactivate and degrade 
antiproteases including elafin [104], alpha-1 antitrypsin and secretory leukocyte inhibitor [105]. 
As a consequence of the proteases/antiprotease imbalance, lung tissue is irreversibly 
damaged, dramatically reducing lung function and ultimately causing respiratory failure [106]. 
In short, HTS therapies that may modulate exuberant oxidase and degranulation activity may 
be used as powerful anti-inflammatories within the setting of CF airways disease. 
  A number of in vitro investigations have documented that sodium chloride slows 
neutrophil activity [107] and a study evaluating the effect of HTS on the mechanisms of 
activation of the NADPH oxidase revealed that stimulated translocation of p67phox to the 
neutrophil membrane in response to PAF was prevented. Moreover, in in vitro cell-free 
oxidase assays, the membrane content of p67phox post PAF activation was increased in 
support of oxidase activity, whereas control unstimulated and HTS-PAF activated 
membranes contained equivalent p67phox protein content [108]. Although these results support 
the potential of HTS to modulate oxidase activity, the concentration of HTS utilised was 
180mmol/L, which is below therapeutic HTS and therefore higher concentrations of HTS 
should be investigated to determine the effect on p67phox membrane translocation. 
Nevertheless, the inhibitory effect of HTS on a second stimuli involving fMLP-induced 
NADPH oxidase was also confirmed. The described inhibition occurred in a dose-dependent 
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manner with results indicating that transient increases in osmolality caused prolonged 
suppression of neutrophil O2- production to the outside of the cell, as measured by 
cytochrome c reduction [83]. The mechanism of inhibition was explored and shown to involve 
blockade of mitogen activated protein kinase (MAPK) ERK 1/2 and p38 signalling [83]. 
Moreover, H2O2 production to the outside of the cell post fMLP activation was equally 
reduced by two concentrations of HTS ([Na+] = 180mmol/l and 200mmol/l) [109]. In contrast 
however, and of major importance, intracellular formation of reactive oxygen species upon 
bacterial phagocytosis was potentiated with increasing osmolar strength [110]. Despite osmotic 
down-regulation of p38 and ERK-1, this later study demonstrated enhanced intracellular O2- 
generation in response to bacterial challenge suggesting that HTS may attenuate tissue injury 
by compromising neutrophil cytotoxic capacity, and additionally appears to enhance the 
response to bacteria. This may be a further beneficial role of HTS when aerosolized clinically 
in CF [110]. 
With respect to the ability of HTS to modulate the degranulation process, Junger and 
co-workers (1998) demonstrated that neutrophils exposed to >50mM HTS alone released 
increased levels of MPO and NE, however, when cells were exposed simultaneously to 
inflammatory levels of fMLP and increasing concentrations of HTS, as would be expected in 
the CF airways, the fMLP-stimulated primary granule release of MPO [20] and NE was 
inhibited in a dose dependent manner [83]. Moreover, HTS induced changes in the actin 
cytoskeleton have been reported [111] and linked to the hypertonic inhibition of neutrophil 
degranulation. HTS instigated a twofold increase in F-actin formation and abrogated the 
mobilization of all granule types suggesting cytoskeletal remodelling as a key component in 
the neutrophil-suppressive anti-inflammatory effects of HTS [112]. As neutrophils in 
individuals with CF demonstrate enhanced secretion of NE and MPO, the potential of 
aerosolized HTS to prevent primary granule release would have tremendous clinical 
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implications. Furthermore, despite the fact that there is abundant extracellular neutrophil 
released hCAP-18/LL-37 in the lungs of individuals with CF, the lung fluid from patients 
exhibits poor antimicrobial activity. A recent study has demonstrated that the antimicrobial 
activity of endogenous hCAP-18/LL-37 in CF BAL fluid is rendered inactive by binding 
GAGs but is liberated following nebulized HTS [113]. The effect of HTS on levels of 
additional antimicrobial peptides and proteins within the CF airways was not evaluated but 
this study does suggest that a strategy whereby nebulized HTS augments antimicrobial 
activity may provide optimization of the innate antimicrobial activity in the setting of CF. 
 
Conclusion 
HTS treatment is associated with an improvement in lung function and marked benefits with 
respect to exacerbations [26, 64, 114, 115]. Significant inflammation in the airways manifests from 
a very young age in CF most likely due to a combination of intrinsic innate immune 
dysregulation and infection. The obvious most effective treatment remains correction of 
CFTR dysfunction at a very early age, thereby curtailing development of airway 
inflammation. However, in the absence of CFTR ion channel modulators for each individual's 
genotype it will remain important to modulate or suppress the inflammatory reactions of the 
disease. Although in children with CF, the use of inhaled HTS did not reduce the rate of 
pulmonary exacerbations [116], the described studies in the present review demonstrate 
dramatic in vitro effects of HTS on neutrophil function, limiting cellular processes that 
govern airway inflammation including cell adhesion, reactive oxygen species production and 
protease release. These reports support the concept that HTS may have beneficial anti-
inflammatory effects other than simply increasing mucociliary clearance and thus further 
investigations of the potential mechanisms of this currently available therapy in CF is 
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Figure 1: Classification of CFTR
according to their effect on CFTR function. Class I mutations affect biosynthesis, while class 
II mutations affect protein processing. Milder mutations such as class II to Class V impair 

















 mutations. CFTR mutations are classified into six groups 
 
  
Figure 2: The effect of HTS on the airway surface liquid (ASL) in CF. 
A) In healthy airway epithelia, CFTR plays a vital role in regulating hydration of the ASL 
constructed of the periciliary 
individuals with CF, Cl- secretion is impaired and Na




layer (PCL) and the mucus layer. B) Due to defective CFTR in 
+




height. C) Treatment with HTS assists osmosis of water into the ASL and thus rehydrates the 


















































Figure 3: HTS reduces levels of IL
migration. 
A) The chemokine IL-8 is a key mediator of inflammation in patients with CF and increases 
neutrophil migration to the airways. GAGs possess the ability to influence the chemokine 
profile of the CF lung by binding IL
B) HTS functions to disrupt IL
proteolytic degradation. Clinical application of HTS may serve to decrease the inflammatory 





















-8 in CF airway samples thereby reducing neutrophil 
-8 and protecting it from proteolytic degrad






Figure 4: Schematic illustration of the 
cells. The neutrophil NADPH
derived toxic products in response to bacteria or a variety of soluble stimuli (fMLP). A
enzyme is dormant in resting neutrophils. The active site of this enzyme is located in an 
integral membrane cytochrome, b
(α & β subunits). B) Stimulation of the neutrophil by fMLP
phosphorylation (P) of a number of kinase
active GTP-bound form and the phosphorylation of the cytosolic components
p47phox and p40phox) occurs. D) These subunits then translocate to the membrane where they 





NADPH oxidase of resting and fMLP activated 
 oxidase generates superoxide (O2-) and secondary oxygen
558, which consists of the two subunits gp91
 induces activation and 
s including Akt. C) p21rac is converted into the 










Figure 5: Components of neutrophil granules
The second mechanism of bacterial killing is mediated by enzymes stored in granules. 
Essential serine proteases stored in primary granules include NE, cathepsin G and proteinase 
3. Other bactericidal proteins of primary granules include defensins, azurocid
bactericidal permeability-increasing (BPI) protein, which mu
bacterial membranes. Additional antibacterial proteins stored in secondary or specific 
granules include lactoferrin, the 18
and lysozyme. Lactoferrin, an iron binding protein displays antimicrobial properties by 
limiting iron availability and exhibits direct antmicrobial and antifungal properties 
independent of iron-binding. LL
integrity of bacterial membranes and can neutralise bacterial endotoxins. The gelatinase or 
tertiary granules contain mainly gelatinase (MMP
V collagen in the extracellular matrix
granule types, neutrophils also contain secretory vesicles that contain a reservoir of essential 
receptors and integrins. All are degranulated to the outside of the cell or into the phagocytic 




















tually function to destabilise 
-kDa human cathelicidin antimicrobial protein (hCAP18) 
-37, the CX-terminal peptide of hCAP
-9) whose main function is to degrade type 
 to aid neutrophil migration. In addition to these three 
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Figure 6: The potential effects of active NE in CF.
Excessive NE activity can lead to proteolysis causing protease
cleaving protease inhibitors. Cleavage of matrix proteins and surface receptors leads to tissue 
damage and prolonged immune response, respectively. NE can further activate pro
inflammatory molecules (MMPs and ADAM
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